Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled time : 13:15 save search
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
treatment phase 2 nash phase 2b
Galecto Hosting a Key Opinion Leader Webinar on GB1211: A Potential Treatment For Non-Small Cell Lung CancerMonday, November 8th @ 10:30am ET
Published: 2021-10-28 (Crawled : 13:15) - biospace.com/
GLTO | $0.6501 -7.21% -7.77% 76K
|
Health Technology
|
| O: -0.91%
H: 2.13%
C: 1.83%
gb1211 treatment lung cancer potential cancer
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
MNPR | $0.63 -3.08% -3.17% 39K
|
Health Technology
|
| O: 4.88%
H: 7.64%
C: 3.31%
treatment phase 1 phase 1b trial phase 2b soft tissue
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
Published: 2021-10-15 (Crawled : 13:15) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.22%
H: 0.74%
C: 0.16%
treatment europe positive risankizumab chmp
Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
Published: 2021-10-12 (Crawled : 13:15) - biospace.com/
ATXS | $9.02 -6.43% -6.87% 660K
|
Manufacturing
|
| O: 0.0%
H: 5.68%
C: 4.47%
disease treatment rare hereditary angioedema
Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
Published: 2021-10-07 (Crawled : 13:15) - globenewswire.com
GLUE | $5.46 -1.44% -1.47% 83K
|
Professional, Scientific, and T...
|
| O: 0.1%
H: 3.64%
C: -2.44%
treatment rosa potential molecular cancer preclinical pre-clinical
Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
Published: 2021-10-07 (Crawled : 13:15) - globenewswire.com
IKNA | $1.31 -2.96% -3.05% 150K
|
Manufacturing
|
| O: 0.28%
H: 11.59%
C: 8.9%
treatment potential cancer conference
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Published: 2021-10-06 (Crawled : 13:15) - biospace.com/
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: -0.51%
H: 5.45%
C: -7.68%
disease alzheimer treatment phase 3 trial refocus-alz rethink-alz alzheimer’s alzheimer's disease alzheimer's
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza
Published: 2021-10-06 (Crawled : 13:15) - biospace.com/
COCP | $1.562 -1.39% 3.9K
|
Health Technology
|
| O: 3.08%
H: 1.0%
C: -2.5%
treatment phase 1 influenza cc-42344 clearance
C-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities
Published: 2021-10-04 (Crawled : 13:15) - biospace.com/
ARAY | $2.2 -0.9% -0.91% 290K
|
Health Technology
|
| O: 0.49%
H: 0.49%
C: -1.23%
treatment cancer breast cancer
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -0.53%
H: 2.39%
C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted grant designation
Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
ZLAB | $15.66 3.57% 3.45% 430K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -0.53%
H: 2.39%
C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted designation
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Published: 2021-09-27 (Crawled : 13:15) - biospace.com/
ATRA | $0.7101 -1.18% -1.2% 700K
|
Health Technology
|
| O: 1.0%
H: 3.09%
C: 1.75%
disease treatment europe positive iot tab-cel cel
Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage
Published: 2021-09-27 (Crawled : 13:15) - globenewswire.com
ACST | $2.9 0.69% 0.69% 8.4K
|
Health Technology
|
| O: 0.0%
H: 5.31%
C: 0.88%
treatment drug
AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
Published: 2021-09-20 (Crawled : 13:15) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -1.33%
H: 1.31%
C: 0.28%
disease treatment fda risankizumab order
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
Published: 2021-09-08 (Crawled : 13:15) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K
|
Professional, Scientific, and T...
|
| O: 19.11%
H: 3.61%
C: 0.85%
disease treatment positive topline parkinson
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
Published: 2021-09-07 (Crawled : 13:15) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 1.23%
H: 1.51%
C: -2.39%
new drug disease treatment fda oxbryta children drug fda acceptance
Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery
Published: 2021-09-01 (Crawled : 13:15) - biospace.com/
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -0.15%
H: 1.57%
C: 1.31%
treatment injection results
Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis
Published: 2021-08-24 (Crawled : 13:15) - prnewswire.com
MDT | $80.38 -1.12% 0.0% 5M
|
Health Technology
|
| O: 0.23%
H: 4.62%
C: 2.94%
treatment fda fda approval approval
AcQMap 8, Acutus Medical’s Innovative Suite of Software Upgrades, Receives FDA Clearance and CE MarkEnhanced Software Automatically Identifies Regions of Interest During the Treatment of Complex Atrial Arrhythmias
Published: 2021-08-11 (Crawled : 13:15) - biospace.com/
AFIB | $0.169 0.06% 0.06% 47K
|
Health Technology
|
| O: 0.63%
H: 1.04%
C: -0.41%
fda clearance treatment fda software ce mark trial clearance
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.